Selected Stock Price Target News — July 8, 2026

Barclays downgraded HCA Healthcare ($HCA) to Equal Weight this morning. That’s the first rating cut in a stretch of seven price target reductions. The stretch dates back to late April. Keefe, Bruyette & Woods moved on two insurers the same morning. It cut both The Travelers Companies ($TRV) and Cincinnati Financial ($CINF) to Market Perform. It raised the price target on each one, at the same time. Three downgrades. Two of them came with a higher number attached.

Two Months of Target Cuts End in Barclays’ First Real Downgrade on HCA Healthcare

HCA Healthcare operates hospitals and outpatient care sites across the U.S. First quarter revenue rose 4.3% from a year earlier. It reached $19.109 billion. Net income came in at $1.620 billion, or $7.15 per diluted share. Underneath those headline numbers, HCA lost about $150 million in the first quarter. Enhanced ACA subsidies had lapsed on January 1. It’s an early look at what’s turning into the harder half of the year for hospital operators. Exchange plan admissions fell roughly 15% year over year in the quarter. HCA still expects a 15% to 20% drop in exchange volumes for all of 2026. Much of that is shifting into employer coverage. Some is going straight into the uninsured column. The company reaffirmed 2% to 3% volume growth for the year anyway. An unplanned $200 million bump in Medicaid supplemental payments helped that guidance along. The payments span Texas, Georgia and Tennessee.

Barclays’ Andrew Mok wasn’t reassured by any of it. He downgraded the stock to Equal Weight this morning. He also cut his price target to $427 from $496. Mok cited a need for more clarity on volumes and payor mix. The Medicaid cuts still working through the system were part of it too.

The Cuts Before Today’s Downgrade

Mok wasn’t the first to move a number down. TD Cowen‘s Ryan Langston cut his target to $431 from $500, on June 22. A heavier round of cuts had come earlier, on April 27. RBC‘s Ben Hendrix went to $534 from $593. Truist‘s David Macdonald went to $535 from $546. Wells Fargo‘s Stephen Baxter went to $436 from $481. Mok himself cut to $496 from $551 that same day. Bernstein‘s Lance Wilkes trimmed again on June 4, to $413 from $503. None of those six cuts touched the rating. Mok’s is the first actual downgrade in the group. It lands a day after Cantor Fitzgerald‘s Sarah James lowered her own target to $525 from $588. She kept her Overweight rating.

HCA still carries a Buy-heavy Street. 19 analysts average $502.05, well above Wednesday’s $423.11 close. Macdonald’s Truist record has hit 94.12% of his HCA targets. Mok’s own career record stands at 62.08%. That’s across 641 calls on 32 stocks in healthcare and industrials.

Where The Bulls And Mok Disagree

The bulls haven’t gone away. Hendrix at RBC and Macdonald at Truist both still call HCA a Buy. Their targets sit in the mid $530s. They argue the volume hit is temporary. The Medicaid supplemental payment programs give management real room to offset it, in their view. Mok’s case is narrower. He wants an actual quarter of clean data first, on exchange volumes and payor mix, before he’ll trust the reaffirmed guidance. HCA shares have rebounded 17% off their June lows. Barclays framed that rebound directly as a window for investors to take some profit ahead of the July 24 earnings date.

Mok’s career record sits below both Hendrix’s and Macdonald’s marks on this specific stock. His downgrade lands one trading day after Cantor Fitzgerald trimmed its own target. HCA reports second quarter results on July 24, two and a half weeks out.

A Raymond James Record Target Meets KBW’s Valuation Downgrade on Travelers

Travelers underwrites property and casualty insurance for businesses and individuals. First quarter net income was $1.711 billion, or $7.78 per diluted share. That’s up sharply from $395 million a year earlier. The stock closed Monday at $343.73, above every price target on the Street except one. Raymond James‘s Gregory Peters raised his own target that same day. He went to $400 from $350. It’s the highest number anyone covering the stock has published, and he kept his Strong Buy rating.

Two days later, Keefe, Bruyette & Woods downgraded Travelers to Market Perform from Outperform. But it raised its own target in the same note, to $356 from $342. Commercial property pricing fell 7.1% in the first quarter, the steepest drop on record, as capacity flooded back into the market and competition intensified. Casualty pricing held firm through the same stretch. The industry’s combined ratio is a measure of underwriting profit, where lower is better. It’s projected at 99% for 2026, up from 97.2% in 2024.

The Analysts And Their Track Records

Meyer Shields of Keefe, Bruyette & Woods wasn’t the lone voice moving this week. Barclays’ Alex Scott is the closest thing to a bear left on the stock. He cut Travelers to Underweight from Equal Weight back on June 12. His target went to $295 from $331. JPMorgan‘s Jimmy Bhullar sits on the other side of that call. He upgraded Travelers to Neutral from Underweight on May 26. His own target went to $322 from $305. He’s hit 15 of 15 price targets on the stock so far. Piper Sandler‘s Paul Newsome raised his target too, to $340 from $322, the same day as Bhullar’s call. He has hit 11 of 12 targets on Travelers. Shields’ own record on this stock specifically runs to 9 of 11 targets met, 81.82%.

Peters built his $400 target on one idea: Travelers’ underwriting margins hold up better than the rest of the group as pricing softens. His bet is that the company’s mix skews away from the property lines taking the brunt of that pricing decline. Shields is making close to the opposite argument. In his view, the stock is priced for a good year already. He thinks the softer property cycle is catching up to the stock. It’s happening faster than the price itself has moved. Scott’s Underweight case leans hardest on slowing premium growth. Margin pressure building into next year is the other half of it. That’s the same earnings concern Barclays cited when it first cut the stock back in June, nearly a month before Shields’ move.

The published targets on Travelers now span $295 to $400. Scott’s Underweight sits at the bottom, Peters’ Strong Buy at the top, and Shields’ new Market Perform number, $356, in between. Travelers reports second quarter results on July 17.

A Record Stock Price Doesn’t Stop KBW’s Downgrade on Cincinnati Financial

Cincinnati Financial underwrites property and casualty insurance, mostly for small and mid-sized businesses. The insurer’s first quarter net income swung to $274 million, from a $90 million loss in the same quarter of 2025. Catastrophe losses fell 14.2 percentage points from a year earlier. That drop was the main driver of the swing. Cincinnati Financial hit an all-time high of $192.60 on July 6, capping a 31.3% run over the past year. The stock closed Tuesday at $189.06, above the $183.25 average target of the four analysts AnaChart tracks on the name. Keefe, Bruyette & Woods downgraded the shares to Market Perform from Outperform this morning. But it raised its own price target too, to $201 from $191. That’s a fresh high among that same group of four.

Since a $190 call on April 28, Shields had been raising his Cincinnati Financial target steadily. That’s an increase of $11 in under three months. He never touched the rating until today. Piper Sandler’s Paul Newsome moved in the same direction on May 26. He lifted his own target to $175 from $157, while holding a Hold rating throughout.

Roth MKM‘s Harry Fong has the highest hit rate of the group still active on the name. He’s landed 15 of 16 targets. BMO‘s Michael Zaremski and BofA‘s Grace Carter round out AnaChart’s four tracked analysts. Both are on Buy ratings, with targets in the $165 to $177 range. Zaremski has hit all 8 of his targets on the stock. Carter has hit all 10 of hers. Shields’ own career record spans 627 price targets on 43 stocks, in the insurance and consumer finance space. It runs to 53.61%.

The Case For Staying Long

Shields isn’t second-guessing Cincinnati Financial’s underwriting. He’s arguing the stock already reflects it, and then some. That’s after a year of outperformance against the broader insurance group. Newsome’s Hold rating stands on similar ground. It reflects a strong run, and the passage of time since his last real reason to move, rather than any specific concern with the business. Fong, Zaremski and Carter are still willing to pay up for it. They point to the underwriting discipline this year. Lower catastrophe exposure is the other reason to stay long, even at a fresh high.

At $201, Shields’ new Cincinnati Financial target now sits $26 above Newsome’s $175 at Piper Sandler. It’s $11 above Fong’s $190 at Roth MKM, even with the downgrade attached. Cincinnati Financial has not announced a specific date for second quarter results.

Today’s calls came from Barclays, TD Cowen, RBC, Truist, Wells Fargo, Bernstein, Cantor Fitzgerald, Keefe, Bruyette & Woods, Raymond James, JPMorgan, Piper Sandler, Roth MKM, BMO and BofA. AnaChart tracks 661,383 price targets and 759,654 ratings across 7,191 analysts. That’s across 9,686 tickers, going back to 2008. The full record sits in AnaChart’s analyst price target dataset.